BackAxsome Therapeutics Overview
Axsome Therapeutics Inc

Axsome Therapeutics Target Price

See Axsome Therapeutics's analyst price targets ($300) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$205.49

Average Target Price

$295.2243.7% upside

9 analysts in the last 4 months

High: $380 | Low: $251

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-12Mizuho SecuritiesGraig Suvannavejh$31653.8% upsideOpen
2026-08-11RBC CapitalLeonid Timashev$29744.5% upsideOpen
2026-08-11Morgan Stanley$25122.1% upsideOpen
2026-08-11NeedhamAmi Fadia$26830.4% upsideOpen
2026-08-11Guggenheim$27533.8% upsideOpen
2026-08-11Wells Fargo$25624.6% upsideOpen
2026-07-20BMO CapitalMalcolm Hoffman$31050.9% upsideOpen
2026-07-07RBC CapitalLeonid Timashev$30447.9% upsideOpen
2026-06-11JefferiesAndrew Tsai$38084.9% upsideOpen
2026-05-05Deutsche BankDavid Hoang$28036.3% upsideOpen
2026-05-05Morgan Stanley$24217.8% upsideOpen
2026-05-05Needham$26729.9% upsideOpen
2026-05-05RBC CapitalLeonid Timashev$30247% upsideOpen
2026-05-05Robert W. BairdBrian Skorney$24619.7% upsideOpen
2026-05-05H.C. Wainwright$29041.1% upsideOpen
2026-05-04Oppenheimer$28036.3% upsideOpen
2026-05-04GuggenheimYatin Suneja$26026.5% upsideOpen
2026-05-04Piper Sandler$25825.6% upsideOpen
2026-05-04Cantor Fitzgerald$27232.4% upsideOpen
2026-05-04JefferiesAndrew Tsai$27533.8% upsideOpen
2026-05-04Deutsche BankDavid Hoang$28136.7% upsideOpen
2026-05-04H.C. WainwrightRaghuram Selvaraju$27031.4% upsideOpen
2026-05-01Oppenheimer$25021.7% upsideOpen
2026-04-30Morgan Stanley$2175.6% upsideOpen
2026-04-10UBS$25926% upsideOpen
2026-02-24RBC Capital$2228% upsideOpen
2026-02-24UBS$25122.1% upsideOpen
2026-02-24Morgan Stanley$2070.7% upsideOpen
2026-02-24Guggenheim$2207.1% upsideOpen
2026-02-24Wells Fargo$2021.7% downsideOpen
2026-02-23Wolfe ResearchRudy Li$23011.9% upsideOpen
2026-02-23Truist FinancialJoon Lee$2002.7% downsideOpen
2026-02-23Jefferies$2154.6% upsideOpen
2026-02-19Mizuho Securities$23011.9% upsideOpen
2026-01-21RBC CapitalLeonid Timashev$2196.6% upsideOpen
2026-01-20H.C. Wainwright$26026.5% upsideOpen
2026-01-16Piper Sandler$2238.5% upsideOpen
2026-01-13Robert W. Baird$2091.7% upsideOpen
2026-01-13Wells Fargo$1936.1% downsideOpen
2026-01-08Morgan Stanley$2040.7% downsideOpen
2026-01-06UBS$24820.7% upsideOpen
2026-01-05NeedhamAmi Fadia$2259.5% upsideOpen
2026-01-05H.C. WainwrightRaghuram Selvaraju$2002.7% downsideOpen
2026-01-02GuggenheimYatin Suneja$2050.2% downsideOpen
2025-12-31Mizuho SecuritiesGraig Suvannavejh$2175.6% upsideOpen
2025-12-31OppenheimerJay Olson$2207.1% upsideOpen
2025-11-04H.C. Wainwright$18510% downsideOpen
2025-11-04RBC Capital$1983.6% downsideOpen
2025-11-04Morgan Stanley$1964.6% downsideOpen
2025-11-04Wells Fargo$15723.6% downsideOpen

Axsome Therapeutics (AXSM) FAQ

Axsome Therapeutics's target price stands at $300. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $300 for AXSM implies 43.7% upside versus today's price ($205.49). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Axsome Therapeutics's target price evolved across reporting periods, while the comparison chart places AXSM next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Axsome Therapeutics's reading of $300 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.